by April Breyer Menon | Oct 4, 2026
On September 25, 2026, the Patent Trial and Appeal Board (“PTAB”) issued Final Written Decisions (“FWD”) in PGR2025-00033 and PGR2025-00039 finding all remaining challenged claims of Halozyme’s U.S. Patent Nos. 12,049,652 (“the ’652 patent”) and 12,104,185 (“the ’185...
by April Breyer Menon | Oct 1, 2026
On September 30, 2026, in Case No. 1:26-cv-00222 (D. Del.), in a sealed opinion, the Court granted Janssen’s motion for a preliminary injunction against the commercial launch of Accord and Bio-Thera’s Simponi® / Simponi Aria® (golimumab) interchangeable...
by April Breyer Menon | Oct 1, 2026
On September 30, 2026, the Federal Circuit denied Eli Lilly’s petition for rehearing en banc of CAFC Appeal No. 24-1094, which reversed the District Court’s grant of judgment as a matter of law that found claims of Teva’s U.S. Patent Nos. 8,546,045, 9,884,907,...
by April Breyer Menon | Sep 30, 2026
Download PDF *Denosumab Challenged Claim Types in Litigation: Claims are counted in each litigation, so claims from the same patent challenged in multiple litigations are counted more than once. Within each litigation a claim is counted...
by April Breyer Menon | Sep 30, 2026
Download PDF *Tocilizumab Challenged Claim Types in IPRs: Claims are counted in each IPR, so claims from the same patent challenged in multiple IPRs are counted more than once. Within each IPR, claims are counted only once, whether they are challenged...
